Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moizerto in infants with Atopic Dermatitis
NCT05372653Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- May 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of difamilast in atopic dermatitis (AD), sponsored by Otsuka Pharmaceutical Co., Ltd.. Started May 2022; status: completed.
02
Drugs
difamilast
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05372653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05372653.